Ideaya Biosciences, INC 8-K filings

IDEAYA Biosciences announced positive Q2 2026 financial results, highlighted by a registrational trial success for darovasertib and a strengthened cash position extending runway to 2030.

IDEAYA Biosciences announced the successful closing of its underwritten public offering, raising approximately $323.6 million in net proceeds.

IDEAYA Biosciences and Roche are collaborating on a clinical trial to evaluate IDE892 in combination with RG6505 for MTAP-deleted pancreatic cancer.

IDEAYA Biosciences has filed a new automatic shelf registration statement to maintain its at-the-market equity offering capacity.

IDEAYA Biosciences reported positive Phase 2/3 OptimUM-02 trial results for darovasertib combination, meeting its primary endpoint and paving the way for an NDA submission.

IDEAYA Biosciences announced positive topline results from its Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma.

IDEAYA Biosciences and AstraZeneca have entered into a clinical collaboration to evaluate IDE849 in combination with Imfinzi for extensive-stage small cell lung cancer.

IDEAYA Biosciences announced its Q4 and full year 2025 financial results, reporting $1.05 billion in cash and significant progress in its oncology clinical pipeline.

IDEAYA Biosciences, Inc. provided a business update outlining its key corporate objectives for 2026, focusing on advancing four registrational trials and several clinical programs.

IDEAYA Biosciences presented its precision medicine oncology pipeline, highlighting strong clinical data for darovasertib and a cash runway extending into 2030.

GlaxoSmithKline has terminated its collaboration agreement with IDEAYA Biosciences, returning two clinical programs, while IDEAYA maintains its cash runway into 2030.

GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) has elected to terminate its Collaboration, Option and License Agreement with IDEAYA Biosciences, Inc., impacting two clinical programs.

IDEAYA Biosciences announced strong third-quarter 2025 financial results, driven by a $210 million upfront payment from Servier, extending its cash runway into 2030, alongside significant progress across its oncology pipeline.

IDEAYA Biosciences announced positive median overall survival data for metastatic uveal melanoma and favorable neoadjuvant data for primary uveal melanoma, exceeding historical benchmarks.

IDEAYA Biosciences announced positive interim clinical data for IDE849 in SCLC, darovasertib in uveal melanoma, and IDE397 in urothelial cancer.

IDEAYA Biosciences has entered into an exclusive license agreement with Servier for darovasertib outside the U.S., securing a $210 million upfront payment and potential milestones.

IDEAYA Biosciences announced its second quarter 2025 financial results and provided key updates on its oncology pipeline, including progress in uveal melanoma and lung cancer trials.

IDEAYA Biosciences, Inc. announced the appointment of Joshua Bleharski, Ph.D., as its new Chief Financial Officer and Principal Financial Officer, effective June 26, 2025.

IDEAYA Biosciences, Inc. announced the successful approval of all three proposals at its 2025 Annual Meeting of Stockholders, including the re-election of two Class III directors, the ratification of its independent auditor, and the advisory approval of executive compensation.

IDEAYA Biosciences announces Q1 2025 financial results, highlighting a strong cash position of $1.05 billion and progress in clinical development programs, including darovasertib and IDE849.

Susan L. Kelley, M.D., will not seek re-election to IDEAYA Biosciences' Board of Directors and will transition to chair the company's new Clinical Advisory Board.

IDEAYA Biosciences announces its fourth quarter and full year 2024 financial results, highlighting a strong cash position and multiple upcoming clinical data readouts.

IDEAYA Biosciences appoints Joshua Bleharski as Chief Financial Officer, effective early May 2025.

IDEAYA Biosciences has obtained an exclusive global license outside of Greater China to develop and commercialize SHR-4849, a promising DLL3-targeting antibody drug conjugate, from Hengrui Pharma.

IDEAYA Biosciences announced positive clinical trial updates, including accelerated enrollment in a key melanoma trial and successful FDA meeting, alongside a substantial $302.4 million financing.

IDEAYA Biosciences reports encouraging Phase 1 clinical data for IDE397, showing a 33% overall response rate in patients with MTAP-deletion urothelial and non-small cell lung cancer.

IDEAYA Biosciences will present Phase 1 expansion results for IDE397, a MAT2A inhibitor, at the EORTC-NCI-AACR Symposium in Barcelona.

IDEAYA Biosciences reports encouraging interim Phase 2 clinical data for darovasertib in neoadjuvant uveal melanoma and receives FDA guidance supporting a potential Phase 3 registration trial.

IDEAYA Biosciences announced second quarter 2024 financial results, highlighted by positive clinical data for multiple programs and a significant capital raise to fund operations into at least 2028.

IDEAYA Biosciences has secured an option for an exclusive worldwide license to develop and commercialize a potential first-in-class bispecific antibody drug conjugate program from Biocytogen.